Free Trial

Arbutus Biopharma (ABUS) Competitors

Arbutus Biopharma logo
$3.13 -0.11 (-3.40%)
As of 03:46 PM Eastern

ABUS vs. GMTX, IBRX, TWST, ARWR, APLS, VCEL, RXRX, NAMS, DNLI, and KNSA

Should you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Gemini Therapeutics (GMTX), ImmunityBio (IBRX), Twist Bioscience (TWST), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry.

Arbutus Biopharma vs. Its Competitors

Arbutus Biopharma (NASDAQ:ABUS) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

Arbutus Biopharma presently has a consensus price target of $5.50, suggesting a potential upside of 75.44%. Given Arbutus Biopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Arbutus Biopharma is more favorable than Gemini Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arbutus Biopharma
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Gemini Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Arbutus Biopharma has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500.

Gemini Therapeutics has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -1,196.64%. Gemini Therapeutics' return on equity of -38.78% beat Arbutus Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Arbutus Biopharma-1,196.64% -75.51% -55.81%
Gemini Therapeutics N/A -38.78%-35.88%

Arbutus Biopharma has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arbutus Biopharma$6.17M97.32-$69.92M-$0.41-7.65
Gemini TherapeuticsN/AN/A-$71.87M-$1.00-54.75

In the previous week, Arbutus Biopharma had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 1 mentions for Arbutus Biopharma and 0 mentions for Gemini Therapeutics. Arbutus Biopharma's average media sentiment score of 0.00 equaled Gemini Therapeutics'average media sentiment score.

Company Overall Sentiment
Arbutus Biopharma Neutral
Gemini Therapeutics Neutral

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 20.3% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Arbutus Biopharma beats Gemini Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Arbutus Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABUS vs. The Competition

MetricArbutus BiopharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$600.64M$2.85B$5.45B$8.92B
Dividend YieldN/A2.44%5.22%4.00%
P/E Ratio-7.6520.6327.2720.07
Price / Sales97.32290.56428.46118.22
Price / CashN/A41.7026.2128.59
Price / Book6.157.427.925.58
Net Income-$69.92M-$55.04M$3.17B$248.65M
7 Day Performance1.46%3.70%4.33%7.15%
1 Month Performance-9.91%0.35%2.61%8.13%
1 Year Performance0.48%4.79%34.78%21.59%

Arbutus Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABUS
Arbutus Biopharma
1.4482 of 5 stars
$3.13
-3.4%
$5.50
+75.7%
+3.7%$599.49M$6.17M-7.6390
GMTX
Gemini Therapeutics
N/A$54.50
+0.7%
N/A+17.4%$2.36BN/A-54.5030High Trading Volume
IBRX
ImmunityBio
2.0936 of 5 stars
$2.64
-2.2%
$12.25
+364.0%
-57.5%$2.33B$14.74M-4.55590News Coverage
Gap Up
TWST
Twist Bioscience
4.445 of 5 stars
$36.79
+2.4%
$50.40
+37.0%
-21.4%$2.20B$312.97M-11.32990News Coverage
Positive News
ARWR
Arrowhead Pharmaceuticals
3.7712 of 5 stars
$15.80
-1.7%
$43.71
+176.7%
-34.4%$2.18B$3.55M-11.29400
APLS
Apellis Pharmaceuticals
4.4119 of 5 stars
$17.31
-0.7%
$40.05
+131.4%
-50.4%$2.18B$781.37M-9.67770Analyst Revision
VCEL
Vericel
2.8347 of 5 stars
$42.55
+2.0%
$61.14
+43.7%
-10.5%$2.14B$237.22M1,418.81300Positive News
RXRX
Recursion Pharmaceuticals
1.7485 of 5 stars
$5.06
+0.6%
$7.00
+38.3%
-28.1%$2.06B$58.84M-2.86400
NAMS
NewAmsterdam Pharma
2.2595 of 5 stars
$18.11
-2.5%
$42.89
+136.8%
-0.8%$2.03B$45.56M-9.634Positive News
Analyst Upgrade
DNLI
Denali Therapeutics
4.6247 of 5 stars
$13.99
-0.8%
$33.71
+141.0%
-30.5%$2.03BN/A-5.24430News Coverage
KNSA
Kiniksa Pharmaceuticals International
3.4154 of 5 stars
$27.67
-1.3%
$38.80
+40.2%
+43.9%$2.02B$423.24M-110.68220Analyst Upgrade

Related Companies and Tools


This page (NASDAQ:ABUS) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners